Respiratory

The vaccine is indicated to prevent invasive disease and pneumonia caused by 20 Streptococcus pneumoniae serotypes.

New data from a phase 3 clinical trial demonstrated promising results for tezepelumab in adults and adolescents with severe asthma.

Asthma attacks among Hispanic/Latinx adults decreased significantly.

Omalizumab (Xolair; Genentech) is approved as a prefilled syringe for self-injection for certain patients with asthma, nasal polyps, and chronic hives.

Here’s an overview of what’s in the late-stage pipeline.

Often referred to as “long COVID” patients or “long-haulers,” these patients continue to experience symptoms of illness far past the acute phase of this viral disease.

Many individuals have been asking if they can take things at home, such as vitamins and OTC medications, to decrease their risk of contracting the virus or to self-treat themselves

Pharmacists can guide patients to the best OTC product selections for their symptoms.

Migraine is frequently comorbid with asthma. A new analysis examines whether there is a direct relationship between the 2 diseases.

In a briefing this morning, the Infectious Diseases Society of America (IDSA) stressed the continued importance of COVID-19 control measures that have been there from the start.

Tezepelumab is an investigational biologic for the potential treatment of severe, uncontrolled asthma.

Despite breakthroughs for personalized medicine, barriers still exist in real-world application.

Preventive efforts, renewed interest in vaccinations drive milder flu season.

In this article, we will review the evidence describing a possible link between vitamin D and COVID-19.

On October 22, 2020, the FDA approved remdesivir (Veklury; Gilead) as the first treatment for coronavirus disease 2019 (COVID-19).

Here are some of the top-read FDA approvals covered by Drug Topics® from this year.

Acetaminophen may be the antipyretic choice for many families, but a new study asks whether it could be a problem for children with asthma.

A poster presentation from ASHP Midyear 2020 Clinical Meeting & Exhibition highlighted the pharmacist’s role in improving outcomes in patients with COPD.

In a virtual session held during the ASHP Midyear 2020 Clinical Meeting & Exhibition, experts discussed updates in asthma management, including new data and upcoming guideline changes that will impact pharmacy practice.

A poster presented at the ASHP 2020 Midyear Clinical Meeting & Exhibition highlighted the success of an in-pharmacy pneumococcal immunization campaign.

Pharmacists may be among the first of the prioritized groups to be offered the COVID-19 vaccine once it receives FDA authorization.

Omalizumab (Xolair; Genentech and Novartis) is the first biologic approved for the treatment of nasal polyps that targets and blocks immunoglobulin E.

Interim analysis results from a phase 3 clinical trial reported a vaccine efficacy rate above 90% for BNT162b2. The trial is ongoing until it meets its threshold for confirmed COVID-19 cases.

With the accelerated use of digital health care amid the COVID-19 pandemic, investigators sought to provide evidence of its benefits for patients with COPD.

The UK study examined the cross-sectional association between vitamins A, E, C, and D and respiratory complaints.

Remdesivir (Veklury; Gilead) is the first and only fully FDA-approved treatment for COVID-19.

The study results indicate that clinicians should take cognitive dysfunction into account in the management of COPD.

CBD and its impacts on a protective peptide show that the cannabinoid may reduce lung inflammation and damage.

Results of a phase 3 trial showed clinical benefits with dupilumab (Dupixent; Sanofi and Regeneron) in children with uncontrolled moderate-to-severe asthma.

The meta-analysis accrued data from 18 studies that focused on patients with hospitalized and chronic heart failure.